Bridgeway Capital Management’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Bridgeway Capital Management’s Portfolio IDXG Stock Details IDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,554	Closed	-$77K	–	1500
2015 Q4	$77K	Sell	1,554 -74	-5%	-$8.24K	﹤0.01%	1384
2015 Q3	$291K	Buy	1,628 +1,250	+331%	+$246K	0.01%	1225
2015 Q2	$54K	Hold	378	–	–	﹤0.01%	1468
2015 Q1	$51K	Hold	378	–	–	﹤0.01%	1455
2014 Q4	$68K	Sell	378 -300	-44%	-$53.4K	﹤0.01%	1412
2014 Q3	$163K	Buy	678 +18	+3%	+$6.01K	﹤0.01%	1363
2014 Q2	$289K	Hold	660	–	–	0.01%	1260
2014 Q1	$302K	Hold	660	–	–	0.01%	1242
2013 Q4	$317K	Buy	660 +250	+61%	+$122K	0.01%	1210
2013 Q3	$198K	Hold	410	–	–	0.01%	1318
2013 Q2	$193K	Buy	+410	New	+$186K	0.01%	1277

Other funds holding IDXG

Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bridgeway Capital Management's IDXG Position: Q1 2016 in Review

Bridgeway Capital Management sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2016, closing a stake of 1,554 shares — an estimated $77K sold.

Bridgeway Capital Management first reported a position in IDXG in Q2 2013 and held it in 11 quarters. The position peaked at $317K in Q4 2013. 18 funds tracked by Wall St. Rank hold IDXG as of Q1 2016.

Bridgeway Capital Management reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
Bridgeway Capital Management sold 1,554 Interpace Biosciences, Inc. Common Stock shares in Q1 2016, an estimated $77K.
Bridgeway Capital Management first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 11 quarters.
Bridgeway Capital Management's Interpace Biosciences, Inc. Common Stock position peaked at $317K in Q4 2013.
18 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2016.

Based on Bridgeway Capital Management's 13F filing for Q1 2016, filed 16 May 2016.